Home, home below the range: all five deals this week priced below the range. There were eleven companies on the IPO calendar this week, but only five were ...read more
Edge Therapeutics, which is developing a sustained-release therapy for limiting brain injury after aneurysms, raised $80 million by offering 7.3 million shares at $11, far below the range of $14 to $16. Edge Therapeutics plans to list on the Nasdaq under the...read more
The last week of September has 11 IPOs on the calendar – more IPOs than all of August 2015. Out of 134 offerings so far in 2015, 61 have been health care...read more
Edge Therapeutics, which is developing a sustained-release therapy for ruptured brain aneurysms, announced terms for its IPO on Monday. The Berkeley Heights, NJ-based company plans to raise $85 million by offering 5.7 million shares at a price range of $14...read more
US IPO Weekly Recap: Only five deals get done after massive valuation cuts
Home, home below the range: all five deals this week priced below the range. There were eleven companies on the IPO calendar this week, but only five were ...read more
Edge Therapeutics prices IPO at $11, far below the range
Edge Therapeutics, which is developing a sustained-release therapy for limiting brain injury after aneurysms, raised $80 million by offering 7.3 million shares at $11, far below the range of $14 to $16. Edge Therapeutics plans to list on the Nasdaq under the...read more
Week ahead: 11 IPOs set to price during the week of September 28
The last week of September has 11 IPOs on the calendar – more IPOs than all of August 2015. Out of 134 offerings so far in 2015, 61 have been health care...read more
A cutting edge biotech: Edge Therapeutics sets terms for $85 million IPO
Edge Therapeutics, which is developing a sustained-release therapy for ruptured brain aneurysms, announced terms for its IPO on Monday. The Berkeley Heights, NJ-based company plans to raise $85 million by offering 5.7 million shares at a price range of $14...read more